IMMU - Immunomedics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Immunomedics, Inc.

300 The American Road
Morris Plains, NJ 07950
United States
973-605-8200
http://www.immunomedics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees346

Key Executives

NameTitlePayExercisedYear Born
Dr. Behzad Aghazadeh Ph.D.Exec. Chairman95.02kN/A1971
Mr. Usama MalikCFO & Chief Bus. Officer517.45kN/A1975
Dr. Morris Z. RosenbergChief Technology Officer1.53MN/A1960
Mr. Kurt J. W. AndrewsChief HR Officer391.97kN/A1969
Mr. Scott A. Canute MBAExec. Director83.65kN/A1961
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Corporate Governance

Immunomedics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.